Blueprint Medicines Company Overview
About Blueprint Medicines
Blueprint Medicines (NASDAQ:BPMC) is a biopharmaceutical company dedicated to discovering, developing, and delivering highly selective kinase inhibitors for patients with genomically defined diseases. Their research is driven by a deep understanding of the genetic blueprint of cancer and other disease areas where they believe their therapies can make a significant impact. Despite the complex landscape of molecular-driven disease treatment, Blueprint Medicines is committed to advancing a robust pipeline of precision therapies. Their projects span a range of cancers and hematologic disorders, aiming to address critical unmet medical needs by targeting the molecular aberrations that drive these diseases. The company's objective is to transform the lives of those affected by these conditions through innovative medicines designed with precision and purpose.
Snapshot
Operations
Products and/or services of Blueprint Medicines
- Ayvakit, a precision therapy approved for gastrointestinal stromal tumors with a PDGFRA exon 18 mutation.
- Gavreto, a treatment developed for RET-altered thyroid cancers and non-small cell lung cancer.
- BLU-263, an investigational KIT and PDGFRa inhibitor for indolent systemic mastocytosis.
- BLU-945, a targeted therapy designed for EGFR-mutant non-small cell lung cancer with a focus on overcoming resistant mutations.
- BLU-701, an experimental bi-therapy for EGFR-driven cancers, aimed at addressing treatment resistance.
- BLU-222, a CDK2 inhibitor in development for targeting cell cycle dysregulation in cancers.
Blueprint Medicines executive team
- Ms. Kathryn Haviland M.B.A.President, CEO & Director
- Mr. Alexis A. Borisy A.M.Co-Founder & Director
- Mr. Michael Landsittel CPAChief Financial Officer
- Ms. Christina Rossi M.B.A.Chief Operating Officer
- Dr. Percy H. Carter M.B.A., Ph.D.Chief Scientific Officer
- Dr. Fouad Namouni M.D.President of Research & Development
- Ms. Ariel HurleySenior Vice President of Finance and Principal Accounting Officer
- Ms. Jenna CohenSenior Director & Head of Investor Relations
- Ms. Tracey L. McCain Esq.Executive VP, Chief Legal & Compliance Officer and Secretary
- Ms. Debra Durso-BumpusChief People Officer